Abstract
The flexible and efficient enantioselective synthesis of poison-frog alkaloids has been described using the highly stereoselective conjugate addition reactions as the key step. Several 5,8-disubstituted indolizidines and 1,4-disubstituted quinolizidines have been synthesized according to this strategy. Furthermore, 5,6,8-trisubstituted indolizidne type of poison-frog alkaloid 223A and unique tricyclic poison-frog alkaloid 205B have also been synthesized by sequential use of the above key conjugate addition reaction. Investigations of inhibitory effects of synthetic poison-frog alkaloids on neuronal nicotinic acetylcholine receptors have been conducted, and we found that most of the synthetic compounds showed inhibitory effects on the neuronal nicotinic acetylcholine receptors. Especially, the 5,8-disubstituted indolizidine 235B inhibited the α4 β2-neuronal nicotinic acetylcholine receptors in highly subtype-selective manner. These results suggested that the synthetic alkaloid 235B is a promising lead compound for the drugs designed to treat cholinergic disorders such as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).
Keywords: Michael-type conjugate addition, indolizidine, quinolizidine, piperidone synthesis, nicotinic acetylcholine receptors (nAChRs)
Current Chemical Biology
Title: Synthesis of Poison-Frog Alkaloids and Their Pharmacological Effects at Neuronal Nicotinic Acetylcholine Receptors
Volume: 1 Issue: 1
Author(s): Naoki Toyooka, Hiroshi Tsuneki, Soushi Kobayashi, Zhou Dejun, Masashi Kawasaki, Ikuko Kimura, Toshiyasu Sasaoka and Hideo Nemoto
Affiliation:
Keywords: Michael-type conjugate addition, indolizidine, quinolizidine, piperidone synthesis, nicotinic acetylcholine receptors (nAChRs)
Abstract: The flexible and efficient enantioselective synthesis of poison-frog alkaloids has been described using the highly stereoselective conjugate addition reactions as the key step. Several 5,8-disubstituted indolizidines and 1,4-disubstituted quinolizidines have been synthesized according to this strategy. Furthermore, 5,6,8-trisubstituted indolizidne type of poison-frog alkaloid 223A and unique tricyclic poison-frog alkaloid 205B have also been synthesized by sequential use of the above key conjugate addition reaction. Investigations of inhibitory effects of synthetic poison-frog alkaloids on neuronal nicotinic acetylcholine receptors have been conducted, and we found that most of the synthetic compounds showed inhibitory effects on the neuronal nicotinic acetylcholine receptors. Especially, the 5,8-disubstituted indolizidine 235B inhibited the α4 β2-neuronal nicotinic acetylcholine receptors in highly subtype-selective manner. These results suggested that the synthetic alkaloid 235B is a promising lead compound for the drugs designed to treat cholinergic disorders such as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE).
Export Options
About this article
Cite this article as:
Toyooka Naoki, Tsuneki Hiroshi, Kobayashi Soushi, Dejun Zhou, Kawasaki Masashi, Kimura Ikuko, Sasaoka Toshiyasu and Nemoto Hideo, Synthesis of Poison-Frog Alkaloids and Their Pharmacological Effects at Neuronal Nicotinic Acetylcholine Receptors, Current Chemical Biology 2007; 1 (1) . https://dx.doi.org/10.2174/2212796810701010097
DOI https://dx.doi.org/10.2174/2212796810701010097 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Antiepileptic Potential of Nucleosides
Current Medicinal Chemistry Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals
Current Protein & Peptide Science Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Synthesis and First Evaluation of [<sup>18</sup>F]Fluorocyano- and [<sup>18</sup>F]Fluoronitroquinoxalinedione as Putative AMPA Receptor Antagonists
Medicinal Chemistry Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
Current Drug Metabolism In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology Carbohydrate-Based Drugs in the Treatment of Epilepsy, Depression and Other Affective Disorders
Current Topics in Medicinal Chemistry An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Synthesis and Evaluation of Anticonvulsant Activities of Pyrazol yl Semicarbazones. Part II
Letters in Drug Design & Discovery In-vitro Functionality of Clozapine Biphasic Release Minitablet Using Advanced Statistical Tools
Drug Delivery Letters Pathophysiology of Status Epilepticus Induced by Pilocarpine
Central Nervous System Agents in Medicinal Chemistry Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats
CNS & Neurological Disorders - Drug Targets Editorial: Novel Perspectives in the Treatment of Epilepsy
Current Pharmaceutical Design The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism The Role of Topiramate and Other Anticonvulsants in the Treatment of Alcohol Dependence: A Clinical Review
CNS & Neurological Disorders - Drug Targets HPMC- A Marvel Polymer for Pharmaceutical Industry-Patent Review
Recent Advances in Drug Delivery and Formulation